Lymphoid hemopathy

This trial is testing an experimental therapy called CT0596, which uses a patient's own immune cells that are engineered to recognize and attack multiple myeloma cells. The study includes adults with relapsed or refractory multiple myeloma who have already tried at least three pr…

Researchers are testing a cell therapy made from healthy donor immune cells that are gene edited with CRISPR-Cas9 and engineered to target CD19, a marker on B-cell lymphomas. The trial enrolls about 30 adults with relapsed or refractory B-cell non-Hodgkin's lymphoma. Phase 1 chec…

Researchers are testing a personalized cell therapy called MT-601 in adults with Hodgkin or non-Hodgkin lymphoma that has come back or stopped responding to treatment. MT-601 is made from each participant's own T cells, which are trained in the lab to recognize several targets fo…

Researchers are testing a CAR-T therapy called pCAR-19B in people with CD19-positive B-cell acute lymphoblastic leukemia that has relapsed or stopped responding to standard treatment. Participants receive an intravenous infusion of their own immune cells, which have been engineer…

Researchers are testing a new immune cell therapy called CD5 CAR-T in people with mature T-cell lymphomas that have come back or stopped responding to standard treatment. The trial enrolls about 36 participants, ages 14 to 70, who have few remaining options. Participants receive …

This phase 1 trial tests VV169, a therapy that aims to create CAR-T cells inside the body to fight multiple myeloma. Researchers give VV169 as an infusion to adults whose cancer has returned or stopped responding to at least three prior treatments. The study focuses on safety, fi…

Researchers are testing a new CAR-T cell therapy called C402-CD19-CAR in adults with large B-cell lymphoma that has come back or stopped responding to treatment. The therapy is made from each participant's own T cells, which are modified to target CD19, a marker on lymphoma cells…

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

This trial tests different ways to prepare children and adolescents with acute lymphoblastic leukemia for a stem cell transplant. The goal is to see whether a conditioning regimen without total body irradiation works as well as one with it, and to find the best approach for diffe…

This Phase III trial is testing whether a single infusion of AZD0120, a CAR-T therapy that targets two proteins on myeloma cells, can keep the cancer at bay better than continuous standard treatment. It enrolls adults newly diagnosed with multiple myeloma who are not eligible for…

This trial is testing whether combining anti-CD19 CAR-T cell therapy with the drug lenalidomide can safely and effectively treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. Participants…

This trial tests a new type of cell therapy called KCAT19 for people aged 16 to 65 with advanced B-cell blood cancers that have relapsed or not responded to at least two prior treatments. The therapy uses immune cells from a donor's cord blood, which are modified to recognize and…

This trial is testing whether a treatment plan tailored to each child's genetic risk can improve outcomes for relapsed acute lymphoblastic leukemia. Children and young adults up to age 22 whose leukemia has returned in the bone marrow receive a combination of chemotherapy drugs, …

This nationwide trial is testing whether adjusting chemotherapy intensity based on the amount of leukemia cells remaining after initial treatment (called minimal residual disease, or MRD) can improve outcomes for children and teens with high-risk acute lymphoblastic leukemia (ALL…

This phase 2 trial tests whether adding dasatinib and blinatumomab to standard chemotherapy can improve outcomes for children aged 1 to 19 with very high-risk acute lymphoblastic leukemia. The study focuses on patients with specific genetic markers or who did not respond to initi…

This trial tests whether using advanced genetic testing (NGS) to measure leftover cancer cells after initial treatment can help doctors tailor chemotherapy for children with standard-risk acute lymphoblastic leukemia. Around 116 children aged 1 to 10 will receive a standard chemo…

This large trial is testing whether adding the targeted drugs blinatumomab or venetoclax to standard chemotherapy can improve survival and reduce side effects in children with intermediate- or high-risk B-cell acute lymphoblastic leukemia (ALL). The study compares different sched…

This study compares three different flu vaccines in 60 adults with blood cancers like leukemia or lymphoma. The goal is to see which vaccine triggers the strongest immune response in people with weakened immune systems. Participants will receive one of the vaccines and have their…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This study tests whether a combination of three drugs—calaspargase pegol-mknl, decitabine, and venetoclax—can help control relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) in patients aged 1 month to 21 years. T…

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This phase 2 trial tests a new drug combination for adults newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. The treatment includes CM336 (a bispecific antibody) plus three other drugs. The study aims to see how many patients achieve deep remi…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This study tests whether adding low-dose radiation to the drug elranatamab can better kill cancer cells in people with multiple myeloma that has come back or not responded to treatment and has spread outside the bone. About 34 adults will receive the combination. The goal is to s…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to target a protein called TSLPR found on …

This study tests a combination of four drugs (mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide) in people with relapsed B-cell non-Hodgkin lymphoma. The goal is to see if this mix can shrink tumors or stop the cancer from growing. About 36 adults who have already tried o…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This study tests a new antibody drug called HuL001, given together with two standard myeloma drugs (lenalidomide and dexamethasone), in 21 adults whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see if the combination is safe and can s…

This phase 3 trial is testing whether adding immunotherapy drugs (brentuximab vedotin and nivolumab) to standard chemotherapy (with or without radiation) improves survival for people aged 5 to 60 with newly diagnosed stage I or II classical Hodgkin lymphoma. About 1,875 participa…

This early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…

This early-phase trial is testing an experimental cell therapy called GT719 in 46 adults with relapsed or treatment-resistant B-cell lymphoma or leukemia that tests positive for CD19. The study aims to see if the treatment is safe and how well it works. Participants receive a sin…

This early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This phase 3 trial tests whether mosunetuzumab works better than rituximab for people with a slow-growing type of lymphoma that has not spread much. Both drugs are lab-made antibodies that help the immune system attack cancer cells. About 600 adults with low tumor burden follicul…

This Phase 2 trial is testing a new drug called MEN1703, both alone and combined with another drug called glofitamab, in 178 adults with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The study aims to see if the drugs…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This phase 2 trial is testing a combination of blinatumomab (an immune-boosting drug) with dasatinib or imatinib (targeted pills) and standard chemotherapy for people with a specific type of leukemia called Philadelphia chromosome-positive or Philadelphia chromosome-like B-ALL. T…

This early-stage trial tests a radioactive drug (Lu-177 edotreotide) in children aged 2 to 17 with cancers that have a specific marker (SSTR-positive). The goal is to find the right dose and check safety. About 20 children whose cancer has returned or not responded to prior treat…

This study tests an experimental drug called NX-5948 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments, including BTK and BCL-2 inhibitors. The main goal is to see if the drug can shrink o…

This early-phase trial is testing an experimental antibody called cevostamab, either alone or combined with other drugs (pomalidomide, daratumumab, and dexamethasone), in 126 people with multiple myeloma that has returned or stopped responding to treatment. The main goals are to …

This phase 3 trial compares starting treatment with venetoclax and obinutuzumab right away versus waiting until symptoms appear in people with newly diagnosed, high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. About 247 participants will be randomly assigned t…

This Phase 3 trial tests a new drug called IBI3003 against standard treatments for people with multiple myeloma that has returned or is not responding to therapy. About 255 participants will be randomly assigned to receive either IBI3003 or a standard treatment chosen by their do…

This study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…

This study tests an experimental drug, HDP-101, in people with multiple myeloma or related plasma cell disorders. The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments, including stem cell transplant or are not eligible for…

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to treatment. About 290 adults will be randomly assigned to receive either the new combination o…

This phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This large phase 2/3 trial is testing whether a new immunotherapy drug called MK-1045, when combined with the targeted therapy rituximab, can treat follicular lymphoma better than the current standard of rituximab plus chemotherapy. About 960 people with previously untreated foll…

This study tests whether adding the targeted drug zilovertamab vedotin to standard chemotherapy (R-CHP) helps people with untreated diffuse large B-cell lymphoma live longer without their cancer growing or spreading, compared to the current standard treatment (R-CHOP). About 1,04…

This study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This phase 2 trial is testing a combination of two drugs—CM336 (a bispecific antibody) and isatuximab (a monoclonal antibody)—in 20 people newly diagnosed with multiple myeloma who also have severe kidney impairment. The goal is to see if the treatment can improve kidney function…

This study tests a drug called zilovertamab vedotin in children and young adults whose blood cancers (like certain leukemias and lymphomas) or solid tumors (neuroblastoma, Ewing sarcoma) have come back or not responded to treatment. The goal is to see if the drug is safe and can …

This early-phase trial tests a two-step approach for people with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. First, patients receive intensive chemotherapy (CLAG-M or FLAG-Ida) followed immediately by a reduced-intensity stem …

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

This study tests an experimental immunotherapy called MK-1045 in 200 people with two types of non-Hodgkin lymphoma: follicular lymphoma (slow-growing) and diffuse large B-cell lymphoma (fast-growing). Participants have already tried at least two other treatments without success. …

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

This study tests whether adding two oral medications (sonrotoclax and zanubrutinib) to standard CAR-T cell therapy can improve treatment results for people with mantle cell lymphoma that has come back or not responded to prior treatment. About 40 adults who are already eligible f…

Researchers are testing whether adding cevostamab to pomalidomide and dexamethasone helps people with multiple myeloma whose cancer returned after BCMA CAR-T therapy. The trial enrolls about 45 adults who have had one to four prior treatments, including a BCMA CAR-T therapy and s…

This early study tests a new type of cell therapy for people with follicular lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to target cancer cells and also carry a tracking tag that can be see…

This phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

This study tests an oral drug called revumenib in people with certain types of leukemia that have relapsed or not responded to standard therapy. The trial has two parts: first, finding the best dose, then testing that dose in four groups based on leukemia type. About 447 particip…

This study tests a drug called tovorafenib (DAY101) in children and young adults (ages 6 months to 22 years) with Langerhans cell histiocytosis that has returned or not responded to treatment. The drug works by blocking enzymes that help cancer cells grow. Researchers will check …

This early-phase trial is testing whether combining two drugs—zanubrutinib and odronextamab—is safe for people with Richter's transformation, a rare and aggressive form of blood cancer that arises from chronic lymphocytic leukemia. The study will enroll 23 adults and monitor for …

This study is testing whether people with multiple myeloma that has come back or stopped responding to other treatments can safely take a lower dose of the drug linvoseltamab once their cancer starts to improve. Linvoseltamab works by helping the body's immune cells find and kill…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This phase 2 trial tests whether giving the drug itacitinib before CAR-T cell therapy can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). The study will enroll 27 adults who are eligible for CAR-T treatment. Participants take itacitinib daily from after ce…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This phase II trial is testing whether a combination of venetoclax and rituximab works better than current standard treatments (ibrutinib plus rituximab or zanubrutinib alone) for people with previously untreated Waldenstrom's macroglobulinemia, a rare type of blood cancer. The s…

This study tests two drugs, elranatamab and isatuximab, given as shots under the skin for people with multiple myeloma that has returned or not responded to at least two prior treatments. The goal is to see if the combination can shrink tumors and control the disease. About 30 pa…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This early-phase trial is testing a new CAR T-cell therapy called AUTO1 (obe-cel) in up to 30 children with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The therapy uses the child's own immune cells, which are…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This study tests a drug called binimetinib for people with hairy cell leukemia that does not have the common BRAF gene mutation. The drug targets a different gene, MEK, which is often altered in these patients. The goal is to see if it can shrink or control the cancer in 40 adult…

This study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…

This early-phase trial tests a new treatment for hairy cell leukemia (HCL) that has come back or not responded to standard care. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. Up to 27 adults will receive chemo…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This phase 2 trial is testing whether adding the drug acalabrutinib to standard chemotherapy and rituximab can improve cure rates for people with untreated diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma. About 132 adults with aggressive B-cell lymphom…

This study tests an experimental drug called NEO100 in people with a fast-growing type of brain tumor called high-grade meningioma that remains after surgery, has progressed, or returned. About 30 participants will take NEO100 four times daily in 28-day cycles. The main goal is t…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This phase 3 trial compares an experimental drug, linvoseltamab, to an existing drug, daratumumab, in 270 people with smoldering multiple myeloma at high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the disease longer. Participants wil…

This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…

This study tests whether daratumumab can eliminate tiny amounts of leukemia that remain after chemotherapy in people with T-cell acute lymphoblastic leukemia (T-ALL). About 20 adults whose cancer has come back or not fully cleared will receive the drug. The goal is to see if it c…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This phase II trial compares a new combination of daratumumab and teclistamab against standard treatments for high-risk multiple myeloma that has relapsed or not responded to therapy. About 80 adults will be randomly assigned to either the new combo or usual care. The goal is to …

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This early-stage trial is testing a new treatment called KSVCBD for people with multiple myeloma that has come back or not responded to at least three prior treatments. KSVCBD is a type of CAR-T cell therapy given directly into the body to target two proteins (CD19 and BCMA) on m…

This early-stage study tests a new drug called MTX325 in healthy volunteers and people with mild to moderate Parkinson's disease. The main goals are to check safety, how the body processes the drug, and whether it reaches the brain. If successful, MTX325 might one day slow the pr…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This early-phase trial is testing a combination of two drugs—Hyper-CVAD chemotherapy and venetoclax—in 22 children and young adults whose leukemia has returned or not responded to treatment. The main goal is to find a safe dose and monitor side effects. If the combination proves …

This phase 3 trial is testing a new CAR-T cell therapy called arlo-cel against standard treatments for adults with multiple myeloma that has come back or stopped responding to previous therapies. About 440 participants will receive either arlo-cel or a standard regimen. The study…

This study tests whether injecting sodium thiosulfate directly into abnormal calcium deposits can shrink them and reduce pain. It includes people with three rare conditions: systemic sclerosis, dermatomyositis, and a genetic disorder called iPPSD2. Participants receive up to 11 i…

This study is for older adults with newly diagnosed multiple myeloma who cannot have a stem cell transplant. It compares taking the drugs daratumumab or isatuximab continuously versus stopping after about a year and a half, while continuing other medications. The goal is to see i…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests whether using stem cells from both a half-matched family donor and a cord blood donor can improve survival without cancer returning. It is for people with certain high-risk blood cancers like leukemia or myelodysplastic syndromes. The approach aims to control the…

This study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults aged 65 or older or with other health issues will receive the …

This study tests whether IgPro20 (HIZENTRA), a concentrated antibody solution given under the skin, can prevent infections in people with multiple myeloma who have low antibody levels due to bispecific antibody therapy. About 100 participants will either receive IgPro20 plus stan…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This phase 3 trial is testing a CAR-T cell therapy called tisagenlecleucel that didn't quite meet commercial release standards. It's for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma who have no other approved options. The study will check if th…

This early-phase trial is testing whether a long-acting antibiotic called dalbavancin, given once every 28 days along with a short course of oral antibiotics, can prevent serious bloodstream infections in children and young adults with high-risk leukemia. The study will enroll 29…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This study tests a new treatment called arlocabtagene autoleucel (BMS-986393) for adults with multiple myeloma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The study aims to see if this tr…

This study tests a breathing machine strategy that adjusts pressure based on lung measurements to protect the right side of the heart in 180 adults with moderate to severe lung failure from pneumonia. The goal is to see if this method reduces heart strain and complications compar…

This study tests whether adding sonrotoclax to the standard drug zanubrutinib helps adults with mantle cell lymphoma that has returned or stopped responding to prior therapy. About 300 participants will receive either the combination or a placebo plus zanubrutinib. The main goal …

This study is testing an experimental drug called surzetoclax, alone or combined with other cancer drugs, in about 130 adults with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and see if it can shrink or control…

This early-phase trial tests whether giving patients a special infusion of donor immune cells (with certain T and B cells removed) after a stem cell transplant is safe and can help prevent their blood cancer from coming back. The study enrolls high-risk patients with hard-to-trea…

This study tests whether adding motixafortide to standard G-CSF helps collect more stem cells for a bone marrow transplant in people with multiple myeloma. About 60 Chinese adults with active myeloma will receive either the drug combo or a placebo before stem cell collection. The…

This phase II study is testing a combination of two drugs, enasidenib and azacitidine, in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial enrolls 50 adults with a specific IDH2 gene mutation. The goal is to see if the combinati…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This phase 3 trial is testing a new oral drug, nemtabrutinib, against two standard targeted therapies (ibrutinib or acalabrutinib) in 1,200 people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if nemtabrutinib works at least as well…

This study tests a drug called talquetamab in elderly patients whose multiple myeloma has come back after earlier treatments. The drug helps the body's immune cells attack the cancer. If the drug stops working, another drug called daratumumab may be added. The goal is to see if t…

This phase 3 trial tests an experimental drug called odronextamab, given together with standard chemotherapy (CHOP), for people with diffuse large B-cell lymphoma who have not been treated before or whose cancer has come back. The study compares this new combination to the curren…

This study tests a new drug called AZD3470, alone or with pembrolizumab (Keytruda), in people with certain blood cancers like lymphoma. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 161 adults and teens will take part.

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This study tests a new treatment plan for people with a rare and aggressive blood cancer called BPDCN. The plan combines two targeted drugs (tagraxofusp and venetoclax) with standard chemotherapy to kill cancer cells. The goal is to see if this combination can control the disease…

This phase 3 trial is testing whether a new drug, nemtabrutinib, combined with venetoclax works better than the current standard of venetoclax plus rituximab for people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 735 p…

This study tests a new drug called sonrotoclax, alone or with other medicines, in people with a type of multiple myeloma that has come back or stopped responding to treatment. The trial includes 246 participants and aims to find the safest and most effective dose. Researchers wil…

This study tests a new drug called BMS-986458, which works by breaking down a protein that helps lymphoma cells grow. It is being tested alone or with other lymphoma drugs in people whose non-Hodgkin lymphoma has returned or not responded to prior treatments. The trial aims to fi…

This Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has already been treated with two types of targeted therapy (BTK and BCL2 inhib…

This study tests a new type of CAR-T cell therapy, called UCD19 CAR-T, in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) or B-cell non-Hodgkin lymphoma (B-NHL) that has come back or not responded to standard treatment. The therapy is made locally to sp…

This study tests a new drug, linvoseltamab, alone or with another drug called carfilzomib, against standard treatments for people with multiple myeloma that has returned or not responded to prior therapy. About 915 participants who have had 1 to 3 prior treatments will be enrolle…

This early-stage trial is testing an experimental drug called LP-168, taken as a pill, in adults with B-cell lymphoma that has come back or not responded to standard treatments. The study aims to find the safest dose and check for side effects in about 200 participants. It is too…

This early-phase trial is testing a combination of two drugs—teclistamab and iberdomide—in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to find the safest and most effective dose of iberdomide when used with teclistamab. About 26…

This study looks at whether giving high-dose chemotherapy followed by a transplant of the patient's own stem cells can help people with peripheral T-cell lymphoma stay in remission longer than just watching and waiting. About 294 adults aged 18 to 75 who are in their first comple…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This study tests whether adding daratumumab to standard treatment (bortezomib and dexamethasone) can improve kidney function better than the usual approach (cyclophosphamide, bortezomib, and dexamethasone) in people newly diagnosed with multiple myeloma who also have kidney failu…

This early-phase study tests a new drug called RO7851624 in 160 people with relapsed/refractory multiple myeloma who have tried several standard treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the dr…

This study tests whether a new drug, zilovertamab vedotin, combined with standard chemotherapy (R-CHP) works better than another approved drug combo for people with a specific type of fast-growing blood cancer called GCB diffuse large B-cell lymphoma. About 594 adults who have no…

This study is testing a new oral drug called BGB-16673, which breaks down a protein that helps cancer cells grow, in combination with other cancer drugs. It is for people with B-cell cancers (like certain lymphomas) that have come back or stopped responding to treatment. The tria…

This Phase 2 trial is testing an investigational drug called surovatamig (AZD0486) in adults with relapsed or refractory B-cell non-Hodgkin lymphoma, including follicular lymphoma and large B-cell lymphoma. Participants must have tried at least two prior treatments. The study aim…

This study tests a new drug called asciminib, given with chemotherapy and later with another drug (blinatumomab), in children, teens, and young adults up to age 30 who have a type of leukemia (Ph+ or Ph-like ALL) that has come back or not responded to treatment. The goal is to fi…

This study tests a drug called mirdametinib in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding to treatment. The drug blocks a protein that helps cancer cells grow. About 20 participants will take the drug to …

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This study tests a new drug combination (glofitamab plus gemcitabine and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a better steroid plan can reduce a serious side effect called …

This study tests a new drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the best dose, check side effects, and see if the drug can shrink tumors. The…

This study tests a new way to do stem cell transplants for adults with high-risk blood cancers who don't have a fully matched donor. Doctors will use stem cells from a half-matched (haploidentical) donor and remove certain immune cells to try to prevent severe graft-versus-host d…

This study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…

This study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to im…

This study tests whether a second type of CAR T-cell therapy, targeting CD22, can extend remission in people with B-cell acute lymphoblastic leukemia who have no signs of cancer after initial CD19 CAR T-cell treatment. About 20 children, adolescents, and adults will receive the m…

This study tests whether adding a radioactive drug (177Lu-DOTA-TATE) to standard therapy (octreotide) helps control advanced neuroendocrine tumors of the gut or pancreas better than standard therapy alone. About 240 newly diagnosed patients with slow-growing but high-burden tumor…

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

This study tests whether adding a targeted drug (nemtabrutinib) to a personalized cell therapy (lisocabtagene maraleucel) can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to treatment. About 20 adults will rec…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-phase trial tests whether adding daratumumab (an immunotherapy drug) after a stem cell transplant can safely help control high-risk T-cell acute lymphoblastic leukemia or lymphoma in children, teens, and young adults up to age 39. About 30 participants will receive the…

This study compares a new drug, BGB-16673, to an existing one, pirtobrutinib, in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to prior treatment. About 500 adults will be randomly assigned to one of the tw…

This early-phase study tests a new experimental drug, REGN17372, combined with another drug called linvoseltamab in people with relapsed or refractory multiple myeloma (cancer that has returned or stopped responding to treatment). The main goals are to check safety, find the best…

This study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma. The 30 participants have already tried at least four prior treatments. Researchers will…

This study tests an experimental drug called LBL-034 in people whose multiple myeloma has returned or no longer responds to standard treatments. The trial has two phases: first, finding the safest dose, and then checking how well the drug shrinks tumors. About 342 adults will tak…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This phase 3 trial tests an experimental drug called odronextamab for people with previously untreated follicular lymphoma, a slow-growing blood cancer. The study compares odronextamab alone or with standard chemotherapy to see if it leads to better remission rates. About 822 par…

This phase 2 trial tests a gradual, three-drug combination (isatuximab, dexamethasone, and lenalidomide) in 40 ultra-frail patients newly diagnosed with multiple myeloma. The goal is to see if starting treatment slowly improves how well patients tolerate therapy and their quality…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This phase II trial is testing a combination of two targeted drugs, inotuzumab ozogamicin and blinatumomab, with or without ponatinib, for adults with a type of leukemia called B-ALL. The study includes newly diagnosed older adults and those whose cancer has returned or not respo…

This phase 3 trial is testing whether a new combination of two oral drugs, sonrotoclax and zanubrutinib, works better than the current standard combination (venetoclax plus acalabrutinib) for people with untreated chronic lymphocytic leukemia (CLL). About 500 adults who have not …

This study tests a new oral drug, BGB-16673, designed to destroy a protein called BTK that helps certain blood cancers grow. The trial includes about 645 people with various B-cell cancers (like lymphoma and leukemia) that have come back or not responded to prior treatments. The …

This study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults whose cancer came back after 1 to 3 prior therapies will take part. The goal is to…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This early-stage trial tests a new drug called rocbrutinib combined with standard chemotherapy (R-GemOx) in 42 people with a type of lymphoma (DLBCL) that has returned or not responded to treatment. The main goals are to find a safe dose and see if the combination shrinks tumors.…

This phase II trial is testing a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to treatment. The study aims to see how many patien…

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This early-phase trial is testing whether combining the immunotherapy drug nivolumab with the drug ASTX727 can help shrink or stabilize B-cell lymphomas that have returned or are not responding to treatment. About 32 adults with certain types of lymphoma will receive the combinat…

This phase 2 trial is testing whether a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—can better control chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that has come back or is resistant to treatment. About 168 adults with high-ri…

This early-stage trial is testing a new drug called JNJ-95566692, a trispecific antibody designed to target lymphoma cells. It is given alone or with another drug (JNJ-87801493) to about 130 people whose B-cell non-Hodgkin lymphoma has not responded to or returned after at least …

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This phase 2 trial is testing whether a blood test that measures tumor DNA (ctDNA) can help doctors safely reduce the amount of chemotherapy for people with advanced Hodgkin lymphoma. After two cycles of standard chemo, patients with undetectable ctDNA may receive fewer total cyc…

This phase 2 trial tests a drug called PTX-100 in 115 adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Participants receive PTX-100 by IV infusion over several cycles. The goal is to see if the drug can shrink or eliminate tumors an…

This study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …

Researchers are testing an experimental drug called SY-12321 in adults with advanced cancers that carry an ALK gene change. These include non-small cell lung cancer, inflammatory myofibroblastic tumor, anaplastic large-cell lymphoma, colorectal cancer, pancreatic cancer, and brea…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This early-phase study tests a new drug called HRS-3005 in 190 adults with B-cell blood cancers (like lymphoma or leukemia) that have returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and get a first look at wheth…

Researchers are testing a chemotherapy regimen called CMOP±R in adults newly diagnosed with non-Hodgkin's lymphoma. The regimen combines liposomal mitoxantrone with cyclophosphamide, vincristine, prednisone, and optional rituximab, given in four-week cycles. The study aims to mea…

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This early-phase trial tests two drugs, ruxolitinib and duvelisib, together in people whose T- or NK-cell lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose of duvelisib when combined with a fixed dose of ruxolitinib. About 70 part…

This Phase 3 trial is testing whether a new drug called mezigdomide, combined with two standard drugs (bortezomib and dexamethasone), works better than the current standard combination (pomalidomide, bortezomib, and dexamethasone) for people with multiple myeloma that has come ba…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …

This study tests whether adding daratumumab to standard drugs (bortezomib and dexamethasone) can shrink tumors in people with a rare and aggressive blood cancer called plasmablastic lymphoma that has returned or not responded to prior therapy. About 28 adults will receive the com…

This study tests whether a combination of two non-chemotherapy drugs (vemurafenib and obinutuzumab) causes fewer side effects than the standard chemotherapy-based treatment (cladribine and rituximab) in people with untreated hairy cell leukemia. About 86 adults with a specific ge…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This phase II trial tests two antibodies, glofitamab and obinutuzumab, in 20 people with mantle cell lymphoma that has returned or not responded after CAR T-cell therapy. Glofitamab helps T cells attack cancer by binding to both T cells and lymphoma cells, while obinutuzumab bloc…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This Phase 3 trial tests whether giving immune globulin (IGI) regularly can prevent serious infections in adults with multiple myeloma who are receiving a bispecific antibody therapy. About 183 participants will be randomly assigned to get IGI right away for 12 months or only aft…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This early-stage trial tests a new type of immune cell therapy for people with several kinds of blood cancers that have come back or stopped responding to treatment. The therapy uses natural killer (NK) cells from donated cord blood, which are genetically modified to better recog…

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This early-phase study tests a new drug (glofitamab) combined with two chemotherapy drugs (gemcitabine and oxaliplatin) in about 50 U.S. adults whose diffuse large B-cell lymphoma has returned or stopped responding to prior treatment. The main goals are to check safety and see ho…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-stage trial is testing two drugs, mosunetuzumab and venetoclax, in people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. Mosunetuzumab is given as a shot under the skin, and venetoclax is a daily pill. The study will chec…

This early-phase trial is testing a new type of CAR T cell therapy called Azer-cel, which is made from healthy donor cells rather than the patient's own cells. It aims to treat adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and relat…

This study is observing how well the drug glofitamab works and how safe it is for Chinese adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried one prior treatment. Researchers will track 300 participants receiving glofitamab as part of t…

This phase 3 trial is testing whether adding the targeted drug obinutuzumab to standard radiotherapy improves outcomes for people with early-stage follicular lymphoma. About 190 participants will be randomly assigned to receive either radiotherapy alone or radiotherapy followed b…

This study is testing a new experimental drug called LY4584180 in adults with certain types of blood cancer (like lymphoma) that have not improved after at least two prior treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shr…

This early-stage trial tests a new drug called LY4152199 in about 215 adults with certain types of blood cancer (like follicular lymphoma or diffuse large B-cell lymphoma) that have already been treated. The drug is designed to help the body's immune cells attack the cancer. The …

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This trial tests whether combining brentuximab vedotin and nivolumab can shrink tumors in people with classic Hodgkin lymphoma that has come back or resisted prior treatments. Participants must have already tried brentuximab or checkpoint inhibitors. The drugs work differently: b…

This study tests a new drug called AZD0486, alone or with other cancer drugs, in people with B-cell blood cancers like certain lymphomas and leukemias. The goal is to see if it is safe and helps shrink or control the cancer. About 408 adults will take part in this early-phase tri…

This Phase 3 trial is testing whether the drug surovatamig can help people with a specific type of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) stay in remission longer after their first round of treatment. About 420 participants will either receive suro…

This study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors, lymphoma, or brain tumors that have specific gene changes (ALK, ROS1, or NTRK1-3). The goal is to find the safest dose and see if the drug shrinks tumors. Particip…

This early-stage trial is testing a new drug called TLN-121, alone or with other medicines, in about 180 people whose Non-Hodgkin Lymphoma has returned or stopped responding to prior treatments. The main goals are to check the drug's safety and how the body processes it, while al…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This study tests whether the drug elranatamab can be given safely in an outpatient clinic instead of the hospital for people with multiple myeloma that has come back or stopped responding to treatment. About 46 adults will receive the drug along with a single preventive dose of a…

This early-stage trial tests an experimental drug called ARV-393 in 255 adults with advanced non-Hodgkin's lymphoma that has come back or not responded to other treatments. The drug is taken as a pill and works by breaking down a protein that helps lymphoma grow. The main goals a…

This study is checking the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with other drugs. About 150 adults who completed a previous pirtobrutinib study can join. They…

This phase II trial is testing a combination of three drugs—zanubrutinib, rituximab, and methotrexate—given through the vein and directly into the eye, for people newly diagnosed with primary intraocular lymphoma, a rare cancer of the eye. The goal is to see if this regimen can i…

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This phase 3 trial tests whether a new CAR T-cell therapy, KITE-753, works better than the current standard, axicabtagene ciloleucel (axi-cel), for adults with large B-cell lymphoma that returned or didn't respond to first treatment. About 550 participants will receive one infusi…

This phase 2 trial is testing whether combining a CAR T-cell therapy (axicabtagene ciloleucel) with radiation therapy is safe for people with follicular lymphoma that has returned or not responded to at least two prior treatments. About 20 adults will receive the treatment, and r…

This Phase 1 trial is testing a new type of immunotherapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not gone away. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack leukem…

This early-stage study tests a new drug, PF-07994525, in about 120 adults with advanced multiple myeloma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. The study has two parts:…

This study tests a combination of two drugs, acalabrutinib and rituximab, in elderly or frail patients with untreated diffuse large B-cell lymphoma who cannot receive standard chemotherapy. About 80 participants will receive the drugs orally and by injection. The main goal is to …

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This phase 3 trial is testing whether the oral targeted drug tirabrutinib works better than a standard combination of rituximab and temozolomide for people with relapsed or refractory primary central nervous system lymphoma (PCNSL). About 132 participants will be randomly assigne…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This phase 1 study is testing a combination of three drugs—ziftomenib, venetoclax, and azacitidine—in children and young adults (ages 2 to 21) with acute leukemia that has returned or not responded to treatment. The main goal is to find the safest dose of ziftomenib when given wi…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This study tests a drug called glofitamab, which helps the immune system find and kill cancer cells, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. Some participants receive glofitamab alone, while other…

This phase 2 trial is testing whether a combination of belantamab mafodotin, pomalidomide, and dexamethasone can help prevent high-risk myeloma from returning after a stem cell transplant. About 34 patients who have already responded to transplant will receive the drug combo as m…

This phase 2 trial tests a one-time infusion of WU-CART-007, a CAR-T cell therapy made from healthy donor cells, in 125 people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to see if it can wipe ou…

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This early-stage trial is testing whether combining two drugs, cevostamab and elranatamab, is safe and tolerable for people with multiple myeloma that has returned or not responded to prior treatments. About 120 participants will receive the drugs, and researchers will monitor si…

This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This study tests whether adding the drug selinexor to standard bispecific antibody therapy can help people with relapsed or refractory multiple myeloma achieve deeper remissions. About 27 adults who have already tried at least 4 prior treatments will take selinexor alongside thei…

This Phase 3 study tests whether the experimental drug glofitamab works better than standard treatments (rituximab plus bendamustine or lenalidomide plus rituximab) for people with mantle cell lymphoma that has returned or not responded to prior therapy. About 182 participants wi…

This study is testing several new drug combinations for people with multiple myeloma, a type of blood cancer. The trial is open to 200 participants who have already had some treatment. The goal is to see if these combinations are safe and help control the disease. Because multipl…

This study tests a new drug called SLS009, alone or with other medicines, in people with blood cancers like leukemia and lymphoma that have come back or not responded to treatment. It also includes newly diagnosed patients with high-risk leukemia. The goal is to see if the drug i…

This early-phase trial is testing a new treatment called IMV102 for people with relapsed/refractory multiple myeloma, a type of blood cancer that has not responded to at least three prior therapies. IMV102 is a personalized therapy made from the patient's own immune cells (CAR-T …

This phase 2 trial tests pirtobrutinib, an oral BTK inhibitor, in 40 people with chronic lymphocytic leukemia (CLL) whose disease has returned or stopped responding after treatment with zanubrutinib. Researchers will track BTK mutations before, during, and after pirtobrutinib tre…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This 76-week study tests whether mazdutide, a weekly injection already used for diabetes, can slow memory and thinking decline in 420 adults aged 50-75 with type 2 diabetes and early dementia. Half receive the drug, half a placebo. Researchers will measure changes in thinking ski…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This phase III trial is testing whether adding inotuzumab ozogamicin—a drug that targets cancer cells—to standard chemotherapy can improve outcomes for young adults (ages 18-39) newly diagnosed with B-cell acute lymphoblastic leukemia. About 310 participants will be enrolled. The…

This study looks at whether older adults with mantle cell lymphoma (MCL) who achieve remission can safely stop taking zanubrutinib and restart it only if the cancer returns, instead of taking it every day forever. About 421 people will be randomly assigned to either continuous or…

This Phase 3 trial compares a fixed-duration combination of zanubrutinib and sonrotoclax against continuous zanubrutinib alone in older patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The study will enroll 466 participants to see if the combo i…

This trial tests whether giving blinatumomab, a drug that helps the immune system destroy leukemia cells, before a stem cell transplant can improve outcomes for adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). Participants who are in remission and have no detect…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This early-phase trial is testing an oral drug called VK-2019 in 30 adults with a type of lymphoma (DLBCL) that is linked to the Epstein-Barr virus and has not responded to at least two prior treatments. Participants take the drug daily in 28-day cycles at one of three dose level…

This phase II trial tests whether combining a targeted antibody drug (mogamulizumab) with a procedure that treats white blood cells with light (extracorporeal photopheresis) can better control erythrodermic cutaneous T-cell lymphoma, a rare skin cancer. About 34 adults with advan…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests two drugs, mezigdomide and elranatamab, together in people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 62 adults will take part in this…

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

This Phase III trial is testing whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of brain tumor (IDH-mutated grade 3 astrocytoma). About 408 participants will receive either vorasidenib or a pla…

This early-phase trial tests the safety and best dose of the drug triapine when given together with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that cancer cells need to grow, while radiation kills cancer cells …

This phase II trial tests whether adding either duvelisib or oral azacitidine to standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma that have not been treated yet. About 170 participants will receive one of three treatment combinat…

This study is testing a new type of immunotherapy called liso-cel (Breyanzi) as the first treatment for primary central nervous system lymphoma (PCNSL), a rare brain cancer. The trial is for 65 adults who cannot have a stem cell transplant. Liso-cel is made from the patient's own…

This early-stage trial tests a new antibody drug called 4A10 in 24 people with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoblastic lymphoma. 4A10 targets a protein on cancer cells to block growth signals and help the immune system attack them. The main goal is…

This study tests a specially engineered donor graft called Orca-Q in children and young adults with blood cancers who need a stem cell transplant. The graft is designed to help the new cells take hold and reduce complications. The trial is currently on hold, but aims to enroll 40…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This early-phase trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has returned or not responded to prior treatment. Teclistamab is a bispecific antibody designed to attach to both cancer cells and immune T-cells, helping the immune system attack…

This early-phase trial tests whether giving a second type of CAR T cell therapy (targeting CD22) after the standard CD19 CAR T therapy is safe and feasible for children and young adults with relapsed or hard-to-treat B-cell leukemia. About 20 participants will receive the standar…

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This study tests a new drug called acalabrutinib combined with standard chemotherapy (R-CHOP) in people with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see how well the combination shrinks tumors and how safe it is. Participants will con…

This study tests a new treatment called AZD0120, which uses a patient's own immune cells engineered to attack two targets (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has returned or stopped responding to prior treatments. The study compares AZD0120 t…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This phase 2 trial is testing a combination of three drugs—zanubrutinib, bendamustine, and rituximab—in people with previously untreated Waldenström macroglobulinemia, a rare type of blood cancer. The study will enroll 56 participants to see how well the treatment shrinks or cont…

This study tests a new drug called EMB-07, which is a bispecific antibody that helps the immune system attack cancer cells. It is for people with aggressive B-cell non-Hodgkin lymphoma, either newly diagnosed or whose cancer has come back. The trial will check safety, side effect…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This phase 2 trial is testing whether adding nivolumab to blinatumomab helps children and young adults (ages 1 to 30) with relapsed B-cell acute lymphoblastic leukemia (B-ALL), including those with Down syndrome. Blinatumomab helps the immune system find and kill cancer cells, wh…

This phase 2 trial is testing whether combining venetoclax and zanubrutinib can drive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) into deep remission. The study enrolls adults who either have not been treated before or whose cancer returned at least two…

This early-stage trial tests a new type of cell therapy for children and young adults up to age 21 with a form of leukemia (CD19-positive) that has returned or not responded to treatment. The therapy uses immune cells from a family donor that are engineered in a lab to recognize …

This phase 2 study tests whether the drug elranatamab can lower the chance of multiple myeloma worsening after treatment with idecabtagene vicleucel (a CAR-T cell therapy). The study will enroll 32 adults with relapsed or refractory multiple myeloma. Participants will receive elr…

This study tests whether combining two drugs, obinutuzumab and CC-99282, can control follicular lymphoma in people with a high tumor burden who have not had prior treatment. About 33 adults with stage II–IV disease will receive the combination and be monitored for side effects an…

This study tests a new cell therapy called cemacabtagene ansegedleucel (cema-cel) in adults with large B-cell lymphoma who still have tiny amounts of cancer cells (minimal residual disease) after finishing their first standard treatment. About 250 participants will be randomly as…

This phase 3 trial tests whether the drug triptorelin can protect the ovaries of adolescents and young adults with cancer who are receiving chemotherapy. Chemotherapy can damage the ovaries, making it hard or impossible to get pregnant later. Triptorelin temporarily pauses ovaria…

This study tests whether adding nivolumab to standard chemotherapy (AVD) can better control early-stage Hodgkin lymphoma in patients aged 2 to 21. The treatment is given to 15 participants to see if it is safe and effective. The goal is to improve outcomes while reducing long-ter…

This study compares two drugs, NX-5948 and pirtobrutinib, in about 620 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding after prior treatment with a BTK inhibitor. The main goal is to see which drug…

This study tests a combination of four drugs—iberdomide, bortezomib, dexamethasone, and isatuximab—for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this treatment can shrink or eliminate the cancer. About 75 p…

This phase 2 trial tests whether mosunetuzumab, a newer antibody, works better than the standard rituximab for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). About 70 patients with untreated or previously treated NLPHL will receive one of the two drugs. The main goal is…

This study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…

This early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…

This study tests a drug called CTO1681 in 54 adults with diffuse large B-cell lymphoma who are about to receive CAR-T therapy. The drug is taken three times daily for 15 days to prevent or reduce cytokine release syndrome, a potentially severe immune reaction. Researchers will mo…

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study tests a combination of four drugs—selinexor, carfilzomib, isatuximab, and dexamethasone—in people whose multiple myeloma has come back or stopped responding to treatment. The trial has two parts: first, a small safety run-in to find the right dose, then a larger group …

This phase 1 trial tests an experimental therapy called MDC-CAR-BCMA001 in adults with relapsed or refractory B-cell cancers, including multiple myeloma and diffuse large B-cell lymphoma. The treatment uses a patient's own immune cells, modified to target a protein called BCMA on…

This study tests a new drug called ARC-02, given together with rituximab, in adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to at least two prior treatments. The main goals are to check the safety of ARC-02 and find the best dose, while also looking at whe…

This pilot trial tests a program called TRTME, designed to help hospitalized patients with opioid use disorder begin medication treatment after discharge. The program includes personalized education to correct misconceptions about MOUD, feedback on individual overdose risk factor…

This trial is testing an experimental drug called LIS1, a specially engineered antibody designed to target and attack cancerous T cells. It is for adults with peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatments. The study has two parts: fi…

This phase 3 trial is testing whether adding an experimental drug called inobrodib to a standard two-drug regimen (pomalidomide and dexamethasone) can help people whose multiple myeloma has come back or stopped responding to prior treatments. Participants will be randomly assigne…

This trial tests whether a personalized diet and exercise plan during the first month of chemotherapy can make leukemia cells more sensitive to treatment in older children, adolescents, and young adults with B-cell acute lymphoblastic leukemia (B-ALL). The study also aims to redu…

This pilot study tests whether drinking tea made from soursop leaves can reduce the number of cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) — blood cancers that have not responded to standard treatments. About 20 particip…

This phase 2 trial is testing whether linvoseltamab, an investigational biologic given by infusion, can turn minimal residual disease (MRD) from positive to negative in people with newly diagnosed multiple myeloma. Participants have already received initial combination therapy bu…

This Phase 3 trial compares a modified version of the standard DHAP chemotherapy regimen against the original in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The modified regimen spreads out the cisplatin and cytarabine doses over several days, aiming…

This trial is testing whether taking tirabrutinib daily can help people with primary central nervous system lymphoma (PCNSL) stay in remission longer after their initial chemotherapy has worked. Participants who have achieved complete remission will be randomly assigned to receiv…

This phase III trial is investigating whether adding an experimental drug called BCD-248 to daratumumab can improve outcomes for people with multiple myeloma that has returned or become resistant to treatment. The study will compare this new combination against the current standa…

This trial is testing whether using a hamstring tendon from a parent can safely and effectively reconstruct a torn anterior cruciate ligament (ACL) in children and teenagers whose bones are still growing. The study will enroll 40 patients aged 8 to 17 with ACL tears that need sur…

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This trial investigates whether long-acting injectable antiretroviral drugs can control HIV better than standard oral pills in adults with AIDS-related lymphoma who are also receiving chemotherapy. Participants will receive one of three HIV treatment strategies—oral pills alone, …

This study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…

This trial investigates a personalized cell therapy called CAR-T for children and young adults (ages 5–50) with B-cell acute lymphoblastic leukemia that has relapsed or not responded to standard treatment. The therapy involves collecting a patient's own immune cells, engineering …

This phase 2 trial is testing whether a radioactive tracer called 18F-fluciclovine can detect multiple myeloma better than the standard FDG tracer during PET/CT scans. The study will enroll 60 adults with newly diagnosed or relapsed/refractory multiple myeloma. Each participant w…

This early-stage study tests a new radioactive tracer called [89Zr]DFO-YS5 for PET scans to find multiple myeloma cells that have a specific protein (CD46). About 20 adults with confirmed multiple myeloma will receive the tracer and have a PET scan. The goal is to see if this met…

Diffuse large B-cell lymphoma often responds to standard chemo-immunotherapy, but roughly a third of patients do not respond or relapse early. Researchers at the Grand Hôpital de Charleroi are testing machine learning algorithms to predict which patients are likely to be primary …

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

Researchers are testing inotuzumab ozogamicin, an antibody-drug conjugate, in people with CD22-positive acute lymphocytic leukemia who have already had a stem cell transplant. The trial has two parts: a phase 1 portion to find the highest dose that is safe to give after transplan…

This study tests whether mindfulness-based cognitive therapy (MBCT) delivered through video calls can prevent depression from coming back. 315 adults with recurrent depression in partial remission will be randomly assigned to group MBCT, a self-help manual with minimal video supp…

This trial tests whether a 14-week nature-based program, integrated into kindergarten routines, can enhance mental and physical well-being in children aged 4-6 from deprived areas. It will compare the program to usual activities, measuring outcomes like motor skills, physical act…

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This study tests whether different types of massage can lower anxiety in cancer patients while they receive chemotherapy. Fifty adults who already have high anxiety and are at least one cycle into chemo will receive massage during their infusion sessions. Researchers will measure…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This study tests a program called EASE that combines psychological support with regular symptom checks and early access to palliative care. Researchers want to see if it reduces traumatic stress and physical symptoms in people newly diagnosed with acute leukemia. Half of the 266 …

Researchers are studying whether proton therapy is practical on a national scale and whether it reduces late side effects, such as second cancers and heart damage, compared with standard photon radiation. The trial enrolls adults with Hodgkin or non-Hodgkin lymphoma confined to t…

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin and some large B-cell lymphomas). Participants must be between 18 and 50 years old and have been in remission for 3 to 10 yea…

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This study is testing whether a special gel called StrataCTX can help people with skin reactions from cutaneous T-cell lymphoma (CTCL) or cancer treatments use less steroid cream. Steroid creams can have side effects when used a lot, so finding an alternative is important. The st…

This study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…

This trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…

This study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…

This trial tests whether a dedicated 'return-to-work after cancer' consultation can help people who have been treated for blood cancers like leukemia, lymphoma, or multiple myeloma get back to their jobs. The consultation, led by an occupational health specialist with possible su…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

This study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…

This trial tests an AI-based platform called Gustabor that creates personalized meal plans for cancer patients experiencing taste disorders from chemotherapy. The study includes adults with multiple myeloma or gastrointestinal cancer who have taste changes and mainly eat by mouth…

This study tests whether a tailored physical activity program can help older adults maintain thinking and memory after a stem cell transplant for blood cancers. Participants aged 60 and older will follow a progressive, light-to-moderate exercise plan with support from therapists …

This trial tests a program called ACT, which trains doctors and nurses to have compassionate, structured conversations with blood cancer patients and their families about end-of-life care. The goal is to help patients understand their prognosis and make informed decisions, potent…

This trial tests whether a specially designed website, called Mosaic, can help blood cancer patients who are about to undergo a stem cell transplant feel less distressed and have a better quality of life. Participants are randomly assigned to use either the Mosaic website or a st…

This phase II trial tests whether a plant-derived supplement called chlorophyllin can reduce severe mouth sores caused by high-dose radiation given before a stem cell transplant. People aged 12 to 65 with blood cancers who need total body irradiation as part of their transplant p…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study tests whether regular blood and bone marrow tests using advanced DNA sequencing can better monitor children with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission with CAR T therapy. The goal is to see if these tests can identify who is truly cur…

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study uses non-invasive MRI and MRS scans to measure how well muscle cells produce energy in adults who survived childhood acute lymphoblastic leukemia (ALL). Researchers will compare 60 survivors with low muscle mass to healthy volunteers. The goal is to understand why many…

This study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…

Researchers at Peking University First Hospital are building a prospective cohort of 2,000 people with plasma cell disorders, including multiple myeloma, amyloidosis, and related conditions. Participants give blood, bone marrow, and urine samples before and after treatment, and t…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study looks back at the medical records of about 140 people with a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN) who received chemotherapy as their first treatment. The goal is to see how effective and safe different chemotherapy regimens are …

This study follows up to 1,000 adults with certain slow-growing blood cancers (CLL, SLL, LPL, WM) to track how the diseases change over time. Participants have regular check-ups and blood draws every 6 to 24 months, and may also have optional biopsies or scans for research. No tr…

This study aims to understand why multiple myeloma affects African American, Latino, Asian American, and White patients differently. Researchers will survey 4000 people diagnosed with multiple myeloma in California to learn about factors that may influence who gets the disease an…

This study tracks 100 adults with mycosis fungoides or Sézary syndrome who are starting mogamulizumab, a standard treatment. The drug often causes a rash that can look like the cancer itself. Researchers want to help doctors tell the difference so they don't stop a working drug t…

This study follows 150 adults aged 70 and older with low-grade non-Hodgkin lymphoma to see how their quality of life changes during treatment. Researchers will use questionnaires to track well-being from diagnosis through one year after therapy starts. The goal is to identify whi…

Researchers in China are reviewing medical records of 500 children diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) between 2015 and 2024. The study compares diagnosis, treatment, and survival outcomes, including a subtype called CML-like ALL…

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

This study looks at how viruses change the environment around tumors in people with lymphoma, lung cancer, or anal cancer. Researchers will analyze blood and tumor samples from 254 patients to understand why some cancers resist treatment. The goal is to find new ways to make anti…

This study observes about 350 people with chronic lymphocytic leukemia (CLL) who received the drug acalabrutinib through a UK early access program. Researchers will review medical records to see how long patients went without their cancer worsening and how long they lived. No new…

This study follows 705 adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking zanubrutinib (with or without obinutuzumab). Researchers will track hospital visits, quality of life, and how well the d…

This observational study builds a national registry of people with multiple myeloma in Italy. Researchers collect information from routine care at different hematology centers to describe how patients are diagnosed and treated. The registry tracks overall survival, time to next t…

This study tracks 50 adults with chronic lymphocytic leukemia (CLL) who are starting acalabrutinib alone (no other cancer drugs) to see how long they stay on treatment and why they might stop. It collects real-world data on effectiveness and side effects, filling a knowledge gap …

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …

This study looks at whether men and women experience different side effects from cancer immunotherapy. Researchers will track symptoms and quality of life in 100 adults starting standard immunotherapy. The goal is to better understand how sex and gender influence treatment experi…

This study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…

This observational study is recruiting 300 active-duty service members and military beneficiaries diagnosed with B-cell non-Hodgkin lymphoma. Researchers want to understand how exposure to toxins, genetic differences, and immune system problems are linked to this cancer. Particip…

This study is collecting blood, bone marrow, and leftover tissue samples from 550 people with acute myeloid leukemia or follicular lymphoma. Researchers will analyze the samples to find genetic markers that may predict how well treatments work or why some stop working. The goal i…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study looks at whether people with mild cognitive impairment or dementia also have problems with their autonomic nervous system, which controls automatic body functions like sweating and pupil response. Researchers will use two non-invasive devices, Sudoscan and automated pu…

This study looks at Hodgkin lymphoma survivors who had chest radiation and bleomycin treatment as children. Researchers want to understand how these treatments affect blood flow to the brain and heart-lung function during exercise. About 100 survivors and healthy volunteers will …

This study provides ongoing check-ups for people who received a donor stem cell transplant at the NIH at least three years ago. Researchers will monitor for late side effects, disease return, and overall health. Participants will have yearly visits that may include blood tests, b…

This early-stage study looks at how the liver handles two experimental drugs, AZD9550 and AZD6234, in people with moderate to severe liver problems compared to healthy volunteers. About 28 adults will receive a single injection of one drug. The goal is to see if liver impairment …

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study looks at whether giving fiber supplements to patients undergoing donor stem cell transplants is practical and well-tolerated. The goal is to see if fiber can support nutrition and gut health after the harsh effects of chemotherapy and radiation. The trial will enroll 4…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This study looks at how CAR T-cell therapy, a treatment for blood cancers, might affect thinking and memory in children and young adults aged 5 to 35. Researchers will test participants' memory, attention, and other thinking skills before and after treatment, over up to 3 years. …

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This study looks at blood and skin samples from people with mycosis fungoides and Sézary syndrome, rare types of lymphoma that affect the skin. Researchers want to find biological markers that can predict how the disease will progress and how well a patient might respond to treat…

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This study looks back at the experiences of 60 adults with relapsed or refractory multiple myeloma who received a stem cell transplant from a donor. The goal is to measure how long patients live without their cancer progressing after this procedure. By gathering real-world data, …

This study follows people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who previously received a combination of ibrutinib and venetoclax in the CAPTIVATE trial. Researchers will track their health for up to 10 years to see what treatments they need …

This study follows 1,500 people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases — rare conditions where the virus drives abnormal immune cell growth. Researchers will collect medical history, treatment details, and blood samples to see how the diseases beh…

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …

This study follows children and young adults with acute lymphoblastic leukemia (ALL) who receive CAR-T cell therapy. The goal is to track how long these engineered immune cells persist in the body and identify factors that cause them to disappear. By understanding why CAR-T cells…

This study gathers blood and leftover tissue samples from 200 people newly diagnosed with aggressive non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and T-cell lymphoma. The samples are used to develop and validate blood-based tests that could monitor can…

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This study follows 400 people in Norway with multiple myeloma, plasma cell leukemia, or AL amyloidosis who are receiving newer immunotherapies like teclistamab, elranatamab, or CAR-T cell therapy outside of clinical trials. Researchers will track how well these treatments control…

This study tests a web-based decision-support tool designed to help families and doctors make shared decisions about whether a child should go on chronic home ventilation. Half of the participating families use the tool, while the other half receive usual care. Researchers then m…

This study investigates the long-term heart and lung health of adults who survived childhood acute lymphoblastic leukemia (ALL) or lymphoma. Researchers use advanced MRI and other imaging to detect subtle damage from past chemotherapy, comparing survivors to healthy volunteers. T…